2Q08 worldwide sales of Isentress, Merck's HIV integrase inhibitor approved in the treatment-experienced setting, were $77M. (Merck launched Isentress in the United States in October 2007.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”